Jul 25,2024

New Study Evaluates Use of the Nerivio® REN Wearable for Treatment of Migraine in Children Under the Age of 12

Theranica announced promising results from a study on the Nerivio REN wearable device for treating migraines in children aged 6 to 11. Previously approved for ages 12 and older, the study published in the Annals of the Child Neurology Society demonstrates the device's safety and effectiveness in younger children. The study showed that 72.2% of children experienced pain relief and 36.0% achieved pain freedom two hours post-treatment, with no adverse events reported. Following the results, Theranica aims to expand FDA approval to include children as young as eight.

CLINICAL STUDY

#connected device

#pdt

View Analyst & Ambassador Comments
Go to original news
Jul 10,2024

Researchers Customize AI Tools for Digital Pathology

Scientists from Weill Cornell Medicine and Dana-Farber Cancer Institute have developed AI tools for digital pathology, leveraging high-resolution digital images for disease diagnosis and treatment guidance. Their study, published in The Lancet Digital Health, shows that ChatGPT can be tailored for digital pathology and cancer biology to provide accurate responses and detailed results, aiding pathologists without coding expertise in using complex software. To address information glitches in general LLMs, Dr. Umeton started with a safe, private and secure ChatGPT version implemented at Dana-Farber Cancer Institute (GPT4DFCI). The researchers augmented GPT4DFCI with access to a comprehensive and curated database of the latest developments in digital pathology, consisting of 650 publications from 2022 onward, which added over 10,000 pages of literature.

CLINICAL STUDY

#ai/software

View Analyst & Ambassador Comments
Go to original news
Jul 16,2024

Diabeloop study reveals significative sex differences in insulin requirements for Type 1 diabetes patients

A groundbreaking real-world study involving over 9,000 adults with type 1 diabetes has uncovered important differences between males and females in insulin requirements. The study, conducted across Europe, utilized data from patients using the Diabeloop Generation 1 (DBLG1) hybrid closed-loop insulin delivery device and was published last month in the Journal of Diabetes Science and Technology. The study included 9,036 participants across multiple European countries, with women representing 59% of the cohort. The average study period was 320 days, amassing 2,887,188 days of data. 

CLINICAL STUDY

#closed loop

View Analyst & Ambassador Comments
Go to original news
Jul 08,2024

A Glycemic Status Classification Model Using a Radiofrequency Noninvasive Blood Glucose Monitor

A new peer-reviewed study published by Know Labs in Diabetes Technology and Therapeutics Journal aimed to assess Know Labs' noninvasive blood glucose measurement method for classifying glycemic status using a novel radiofrequency (RF) glucose sensor combined with machine learning. Data were collected from 31 participants with prediabetes or type 2 diabetes using both the RF sensor and traditional glucose meters. The results showed that the machine learning model achieved an overall accuracy of 93.37% in classifying glycemic status. Specifically, the model demonstrated sensitivities of 85.51% for hyperglycemic, 96.63% for normoglycemic, and 50.00% for hypoglycemic statuses. The specificities were 96.92% for hyperglycemic, 84.51% for normoglycemic, and 99.81% for hypoglycemic statuses. These findings suggest that the RF sensor, in conjunction with machine learning, can effectively classify glycemic status, indicating its potential for noninvasive diabetes screening.

CLINICAL STUDY

#cgm

View Analyst & Ambassador Comments
Go to original news
Jul 02,2024

AI Model to Improve Patient Response to Cancer Therapy

Researchers at The Australian National University (ANU), in collaboration with the National Cancer Institute and Pangea Biomed, have developed an AI tool called DeepPT to improve cancer treatment selection. DeepPT predicts a patient's mRNA profile, crucial for personalized cancer medicine, and works alongside another tool, ENLIGHT, to forecast patient responses to various cancer therapies. Trained on data from over 5,500 patients across 16 cancer types, DeepPT improved patient response rates from 33.3% to 46.5%. It also utilizes histopathology images, which are readily available and cost-effective, reducing delays in processing molecular data. The study was published in Nature Cancer.

CLINICAL STUDY

#ai/software

#clinical decision support

View Analyst & Ambassador Comments
Go to original news
Jul 11,2024

Swing publishes Phase III data for fibromyalgia digital therapy

Swing Therapeutics has published positive Phase III trial results for its digital therapeutic, Stanza, which treats fibromyalgia symptoms through self-guided acceptance and commitment therapy (a form of CBT). The 12-week, randomized PROSPER-FM study (NCT05243511) showed that 71% of Stanza users reported improved well-being, compared to 22% in the control group. Stanza also significantly improved fibromyalgia-related symptoms, pain, fatigue, sleep disturbance, and depression. No safety issues were reported. The study's results, published in the Lancet, validate Stanza as an effective, non-drug treatment option for fibromyalgia, addressing the limitations of traditional pharmacological treatments.

CLINICAL STUDY

#mobile app

#cbt

View Analyst & Ambassador Comments
Go to original news
Jul 09,2024

Kaia Health's Digital Therapy Shows Sustained Impact on Pain Reduction, Functional Ability, Mental Health, and Cost-Effectiveness in 12-Month Study

Kaia Health released follow-up results from the Rise-uP study, a randomized controlled trial with over 1,200 participants, showcasing the long-term benefits of their digital therapy for lower back pain. Key findings over 12 months show that Kaia app users reported a 46% pain reduction compared to 24% in the control group. Also, an 81% decrease in overall healthcare costs was observed in the Kaia group, driven by reduced inpatient treatment, medication costs, and work incapacity.

CLINICAL STUDY

#mobile app

View Analyst & Ambassador Comments
Go to original news
Jun 24,2024

Teladoc research shows AI-powered 'nudges' can improve diabetes members' engagement, health outcomes

Teladoc Health presented two studies at the American Diabetes Association’s 84th Scientific Sessions, demonstrating the impact of AI on diabetes management. First study aims to evaluate the effectiveness of AI-powered personalized health nudges. Over nine months, increased engagement led to significant improvements in blood sugar control. Members who received personalized nudges had a 3X increase in engagement, resulting in an additional 0.4 reduction in A1c levels (from 8.2 to 7.8). Teh second study showed  how tailored email content affects engagement with health coaches. AI-driven predictive models suggested personalized next-best actions in weekly emails to members with type 2 diabetes. Members who received these personalized recommendations were 50% more likely to engage with a health coach compared to those who received standard newsletters.

CLINICAL STUDY

#coaching

#mobile app

View Analyst & Ambassador Comments
Go to original news
Jun 17,2024

Talisman needle-free CGM demonstrates strong correlation to blood glucose in clinical studies and moves towards large volume manufacturing

GlucoModicum has provided an update on its Talisman needle-free continuous glucose monitor (CGM), highlighting strong results from clinical studies demonstrating its correlation with blood glucose levels. The device, utilizing magnetohydrodynamic (MHD) technology, extracts interstitial fluid without needles for painless and accurate glucose monitoring. It is nearing large-volume manufacturing readiness with designs for automated production lines capable of manufacturing millions of sensors annually. GlucoModicum has secured substantial funding and is progressing towards CE marking and FDA submission, aiming for commercial launch.

CLINICAL STUDY

#cgm

View Analyst & Ambassador Comments
Go to original news
Jun 11,2024

Sequel Med Tech study backs its automated insulin pump that prevents occlusions

Sequel Med Tech's twiist automated insulin delivery system powered by Tidepool, evaluated in a recent study, demonstrated superior performance in detecting occlusions faster compared to three other commercial insulin pumps in the U.S. The study highlighted twiist's ability to prevent "silent insulin non-delivery" by using an acoustic sensor to measure insulin delivery volume in real-time. FDA-cleared in March, twiist detected occlusions between five and 30 times faster than competitors, with significantly lower pressure at occlusion points, reducing the risk of insulin delivery interruptions and site leakage.

CLINICAL STUDY

#insulin pump

View Analyst & Ambassador Comments
Go to original news
Subscribe to CLINICAL STUDY